Dermatol. praxi. 2023;17(1):38-41 | DOI: 10.36290/der.2023.008

Dupilumab in the treatment of atopic dermatitis

MUDr. Radek Litvik
Kožní oddělení Fakultní nemocnice Ostrava a Lékařské fakulty Ostravské univerzity

Atopic dermatitis (AD) is a common, inflammatory skin disease affecting adults and children with complex immunopathogenesis characterized by a dominant Th2 response. Dupilumab is the first biologic therapy available to treat AD. Its effectiveness and safety were demonstrated in many clinical trials.

Keywords: atopic dermatitis, cytokines, Th2 response, dupilumab.

Accepted: March 23, 2023; Published: March 28, 2023  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Litvik R. Dupilumab in the treatment of atopic dermatitis. Dermatol. praxi. 2023;17(1):38-41. doi: 10.36290/der.2023.008.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Beck LA, Thaci D, Hamilton JD, et al. Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis. N Engl J Med. 2014;371:130-139. Go to original source...
    2. Beck L, Thaci D, Deleuran M, et al. Dupilumab Provides Favorable Safety and Sustained Effiacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. Americal Journal of Clinical Dermatology. 2020;21:567-577. Go to original source...
    3. de Bruin-Weller m, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBETY AD CAFE), BJD. 2018;178:1083-1101. Go to original source...
    4. Ferreira S, Torres T. Dupilumab fot the treatment of Atopic Dermatitis Actas Dermosifiliorg. 2018;109:230-240. Go to original source...
    5. Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155-172. Go to original source...
    6. Chaplin S. Janus kinase inhibitors for autoimmune disorders. Prescriber. 2017;28:33-37. Go to original source...
    7. Chaplin S. Dupilumab for the treatment of atopic dermatitis. Prescriber. 2018:35-37. Go to original source...
    8. Jarnagin K, Chanda S, Coronado D, et al. Crisaborole Topical Ointment, 2% A Nonsteroidal, Topical, Anti-Inflammatory Phosphodiesterase 4 Inhibitor in Clinical Development for the Treatment of Atopic Dermatitis. J Drugs Dermatol. 2016;15:390-396. Go to PubMed...
    9. Litvik R. Atopický ekzém v dospělém věku. In Dermatologie v kazuistikách. Praha: Mladá fronta; 2008.
    10. Matsunaga K, Katoh N, Fuieda S, et al. Dupilumab: Basic aspects and applications to allergic diseases. Allergology Internatiobal. 2020;69:187-196. Go to original source...
    11. Simpson EL, Bieber T, Guttman-Yassky E, et al. Two Phase 3 Trials of Dopilumab versus Placebo in Atopic Dermatitis. N Engl J Med. 2016;375:2335-2348. Go to original source...
    12. Wang C, Kraus Ch, Patel K, et al. Real-world experience of dupilumab treatment fot atopic dermatitis in adults: a retrospective analysis of patients´records. International Journal od Dermatology. 2020;59(2):253-256. doi: 10.1111/ijd.14573. Epub 2019 Jul 8. Go to original source... Go to PubMed...

    Return to the content


    Dermatology for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.